Archive - May 2022
Fennec Pharmaceuticals Announces FDA Acceptance for Filing of New Drug Application Resubmission for Pedmark
Axsome Therapeutics Receives FDA Complete Response Letter for New Drug Application for AXS-07 for the Acute Treatment of Migraine
Coherus and Junshi Biosciences Receive Complete Response Letter from U.S. FDA for Toripalimab BLA
Hutchmed Receives Complete Response Letter from the U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer’s Disease Under the Accelerated Approval Pathway
First treatment option indicated for CKD in Scotland for 20 years
University of Aberdeen study finds diabetes almost doubles risk of COVID-19 death
COVID Vaccine Makers Shift Focus To Boosters